Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-039389
Filing Date
2025-03-14
Accepted
2025-03-14 16:02:43
Documents
107
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K nktr-20241231.htm   iXBRL 10-K 5197531
2 EX-19.1 nktr-ex19_1.htm EX-19.1 206123
3 EX-21.1 nktr-ex21_1.htm EX-21.1 1377
4 EX-23.1 nktr-ex23_1.htm EX-23.1 11050
5 EX-31.1 nktr-ex31_1.htm EX-31.1 13469
6 EX-31.2 nktr-ex31_2.htm EX-31.2 13576
7 EX-32.1 nktr-ex32_1.htm EX-32.1 10532
8 EX-97 nktr-ex97.htm EX-97 42128
9 EX-99 nktr-ex99.htm EX-99 206270
10 GRAPHIC img22399441_0.jpg GRAPHIC 445952
11 GRAPHIC img22399441_1.jpg GRAPHIC 191109
  Complete submission text file 0000950170-25-039389.txt   19417640

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nktr-20241231.xsd EX-101.SCH 2217063
110 EXTRACTED XBRL INSTANCE DOCUMENT nktr-20241231_htm.xml XML 3169446
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-24006 | Film No.: 25739872
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)